Guth has Friedreich’s Ataxia and chose to raise money at Happy Place Nutrition for Friedreich’s Ataxia Research Alliance ...

The Oxford-Harrington Rare Disease Centre ('OHC') today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.

The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Investigators who designed a base-editing treatment are planning an "umbrella of umbrellas" trial, while others are developing roadmaps to guide personalized treatments.

Larimar Therapeutics ( ($LRMR) ) has provided an update. On November 10, 2025, Larimar Therapeutics announced an updated slide presentation ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min National celebrity Bill Nye ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min National celebrity Bill Nye ...